PLUR · Pluri Inc.
$0.95
+0.10 (+11.63%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“According to management estimates, we have sufficient resources to meet our operating obligations for a period of less than three months from the issuance date of our consolidated financial statements, which was September 10, 2026. These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-K filed Sep 10, 2026
Market Cap
$10.49M
Shares
12.34M
Volume · Oct 20
9162
Avg daily vol (3M)
20.96K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.85
Open$0.90
Day$0.85–0.96
52W close$0.85–4.45
Avg vol 30d16K
Short int19K · 0.2% float · 1.0d
Short vol64%
DataJan 2020–Oct 2026
Filing10-K · Sep 10
Up next
filed Sep 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.02M
Trailing 12 months
Net income (TTM)
−$23.82M
Trailing 12 months
Revenue growth YoY
-15.8%
Year over year
Operating margin
-2,454.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-176.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+53.2%
Year over year · more shares
Price change (1Y)
-80.0%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−66%
below
Price vs 50-day avg
−33%
below
RSI (14)
28
oversold
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−75%
trailing
YTD return
−72%
this year
Relative strength
−82%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
3 of 16 funds reported for Sep 30 · net -2 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.16% of float · ▼ -3.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — mid 3-yr range
Squeeze score
29
low risk · 0–100
Fundamentals
Revenue growth
−24%
Y/Y
Gross margin
45%
contracting
EPS growth
+31%
Y/Y
Free cash flow
$-20.2M
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
11.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−66%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
28
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
3 of 16 funds reported for Sep 30 · net -2 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.16% of float · ▼ -3.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $4
vs 200-day avg -66%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLUR
this stock
Pluri Inc.
|
$10.49M | -71.6% | -24.0% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLUR | -12.4% | -20.6% | -74.8% | -15.0% | -71.6% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -10.9% | -19.6% | -82.5% | -15.5% | -84.0% |